Cold forming partnership leads to development of drug delivery system
Dawson Shanahan and Zogenix work together on Sumavel DosePro
Dawson Shanahan partnered Zogenix on development of the Sumavel DosePro (sumatriptan injection) system, a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the acute treatment of migraines and cluster headaches.
‘Our client had heard of the benefits of cold forming in terms of both quality and manufacturing cost savings and approached us to produce one component of the DosePro device by cold forming,’ said Mark Jennings at Dawson Shanahan. ‘They were so impressed with our innovative solution that they then asked us to make a second component, again to demanding tolerances.’
Dawson Shanahan began to work closely with Zogenix to enhance the design of the DosePro system and manufactured a number of integral elements of the system in-house. With assistance from Simon West at E-Tech, the company created the bespoke machining and tooling needed to manufacture one of the components and together they developed and tested the parts until an optimum solution was found.
Dawson Shanahan engineered an aluminium chamber and steel ram to administer the drug without requiring a needle. The company says the success of the design is partly due to the high quality finish and intricate production of the cold-formed parts, which make it possible for the administration mechanism to work.
‘Throughout the manufacture process, Dawson Shanahan has been extremely collaborative, throwing the necessary resources at challenges to help us find the best solutions,’ said Bill Feinstein, director of operations planning and procurement at Zogenix.
Established in 1945, Dawson Shanahan employs 55 people in its 2,800m² purpose-built factory. The company is a precision manufacturer of components using cold forming, precision CNC machining and assembly. It specialises in the cold forming and finish machining of pure copper (OFHC), aluminium and ferrous components.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Sustainability
Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system
A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient safety. The integrated label concept, developed with Schreiner MediPharm, offers reliable first-opening indication, oxygen and light protection, and can include an RFID chip for accurate drug traceability and inventory management. A carton secondary packaging eliminates the need for blister packs, reducing waste and saving valuable storage space in hospitals and during transport, thereby cutting the carbon footprint of the entire value chain by up to 58%
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation